Compare PCRX & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | TRIP |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2010 | 2011 |
| Metric | PCRX | TRIP |
|---|---|---|
| Price | $36.35 | $9.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 16 |
| Target Price | ★ $33.57 | $13.36 |
| AVG Volume (30 Days) | 2.1M | ★ 3.4M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.44 | ★ 675.00 |
| EPS | ★ 0.19 | N/A |
| Revenue | $541,533,000.00 | ★ $1,556,000,000.00 |
| Revenue This Year | $3.84 | N/A |
| Revenue Next Year | $4.73 | $3.35 |
| P/E Ratio | $191.29 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $8.02 |
| 52 Week High | $36.67 | $17.82 |
| Indicator | PCRX | TRIP |
|---|---|---|
| Relative Strength Index (RSI) | 83.97 | 54.14 |
| Support Level | $21.78 | $9.03 |
| Resistance Level | N/A | $11.76 |
| Average True Range (ATR) | 0.40 | 0.31 |
| MACD | 0.89 | 0.16 |
| Stochastic Oscillator | 97.44 | 73.11 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.